Evidence map›Paper›PMID 40775238›Full record

ArticleNPJ breast cancer2025

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

Eva Valentina Klocker, Nina Dobrić, Ricarda Graf, Christine Beichler, Dominik Hlauschek, Christoph Suppan, Lara Pancheri, Daniel Egle, Carmen Albertini, Rupert Bartsch and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Eva Valentina KlockerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Nina DobrićDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Ricarda GrafInstitute of Human Genetics, Diagnostic, and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Christine BeichlerInstitute of Human Genetics, Diagnostic, and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Dominik HlauschekDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Christoph SuppanDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Lara PancheriDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Daniel EgleDepartment of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Carmen AlbertiniDepartment of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Rupert BartschDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Angelika Martina StarzerDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Philipp Jakob JostDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Gabriel RinnerthalerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Ellen HeitzerInstitute of Human Genetics, Diagnostic, and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Nadia Dandachi *Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. nadia.dandachi@medunigraz.at.
Marija Balic *Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. balicm@upmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hormone receptor-positive (HR + )/HER2-negative (HER2 - ) breast cancer is the most common subtype, with biomarker-driven therapies improving outcomes. Circulating tumor DNA (ctDNA) analysis enables minimally invasive assessment of somatic alterations to guide therapy. However, assay choice impacts clinical utility, and access remains inconsistent. This study compares single-gene and panel-based sequencing for assessing PIK3CA mutations and broader genomic profiling. We conducted a prospective, multicenter study analyzing 161 plasma samples from 146 patients before initiating a new line of palliative therapy using the SiMSen-Seq (SSS) assay for PIK3CA hotspot mutations, the AVENIO ctDNA Expanded assay (77 genes) and mFAST-SeqS for tumor fraction estimation. High concordance (92.6%) was observed between SSS and AVENIO for PIK3CA mutations. AVENIO identified additional actionable alterations, including ESR1 (17.5%) and PI3K pathway alterations (40.6%), and together with tumor fraction estimation, improved interpretation of negative liquid biopsy findings. These findings support broader ctDNA profiling in clinical practice while highlighting accessibility challenges.

Identifiers

PMID40775238
PMCPMC12331942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.